DS
Therapeutic Areas
Dr. Reddy's Laboratories Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Generic Semaglutide Injection (Obeda) | Type 2 Diabetes | Approved |
| Generic Semaglutide (Oral) | Type 2 Diabetes, Obesity | Development |
| Bevacizumab Biosimilar | Various Cancers | Approved |
| Rituximab Biosimilar | Non-Hodgkin Lymphoma, Rheumatoid Arthritis | Approved |
| Lenacapavir | HIV-1 Infection | Approved |
| Toripalimab | Recurrent/Metastatic Nasopharyngeal Carcinoma | Approved |
| CAR T-Cell Therapy Program | Relapsed/Refractory Multiple Myeloma | Development |
| Injectable Contraceptive | Women's Health / Family Planning | Development |
Leadership Team at Dr. Reddy's Laboratories
EI
Erez Israeli
Chief Executive Officer
MR
M.V. Ramana
CEO, Branded Markets
DM
Dr. Murali Ramachandra
Chief Executive Officer, Aurigene Oncology
KV
Krishna Venkatesh
Global Head of Quality and Pharmacovigilence
DK
Dr. Kallam Anji Reddy
Founder